UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Blood, 2010-09, Vol.116 (12), p.2040-2045

2010

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

Clinical cancer research, 2019-07, Vol.25 (14), p.4224-4230

2019

Link zum Volltext

Verfügbarkeit prüfen

Chlorambucil in Indolent Chronic Lymphocytic Leukemia

The New England journal of medicine, 1998-05, Vol.338 (21), p.1506-1514

1998

Link zum Volltext

Verfügbarkeit prüfen

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Leukemia, 2014-03, Vol.28 (3), p.675-679

2014

Link zum Volltext

Verfügbarkeit prüfen

Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review

Leukemia & lymphoma, 2008-01, Vol.49 (9), p.1762-1768

2008

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (ifm 2012-03)

Clinical cancer research, 2019-05, Vol.25 (14)

2019

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Good Prognosis CD20+ Large-Cell Lymphomas in Patients Aged 65 to 80, with 3 Cycles of R-CHOP14 Followed by An Injection of 90Y Ibritumomab Tiuxetan

Blood, 2008-11, Vol.112 (11), p.4937-4937

2008

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL

Blood, 2015-12, Vol.126 (23)

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of short CHOP-rituximab combination with early consolidation with ibritumomab-tiuxetan-Y 90 (IT-Y 90 ) in non-pretreated patients age 65 to 80 with CD20+ diffuse large B-cell lymphoma (DLBCL)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.6633-6633

2012

Link zum Volltext

Verfügbarkeit prüfen

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Clinical lymphoma, myeloma and leukemia, 2018-10, Vol.18 (10), p.e401-e419

2018

Link zum Volltext

Verfügbarkeit prüfen

Light Chain Escape in Multiple Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.1881-1881

2018

Link zum Volltext

Verfügbarkeit prüfen

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy

Antiviral therapy, 2005, Vol.10 (1), p.53-61

2005

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e7-e8

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(41)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Humans
(24)
Female
(23)
Male
(23)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Adult
(17)
Middle Aged
(15)
Pharmacology. Drug Treatments
(14)
Infectious Diseases
(12)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(11)
Immunology
(11)
Antiviral Agents
(10)
Hiv Infections - Drug Therapy
(10)
Treatment Outcome
(10)
Immunodeficiencies. Immunoglobulinopathies
(8)
Immunopathology
(8)
Life Sciences
(8)
Virology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome Experience

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

Chlorambucil in Indolent Chronic Lymphocytic Leukemia

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group

Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (ifm 2012-03)

IFM2012-03

Treatment of Good Prognosis CD20+ Large-Cell Lymphomas in Patients Aged 65 to 80, with 3 Cycles of R-CHOP14 Followed by An Injection of 90Y Ibritumomab Tiuxetan

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL

Phase II study of short CHOP-rituximab combination with early consolidation with ibritumomab-tiuxetan-Y 90 (IT-Y 90 ) in non-pretreated patients age 65 to 80 with CD20+ diffuse large B-cell lymphoma (DLBCL)

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B

Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

Light Chain Escape in Multiple Myeloma

In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy

GMCLI, Goelams Mantle Cell Lymphoma Index, a New Prognostic Index of Survival for MCL Patients Treated with VAD-C and Autologous PBSCT

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Suchergebnisse filtern